Fda provides feedback and reaches consensus on nexalin's design for planned anxiety and insomnia clinical studies of its gen-3 halo clarity™ headset device

Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024 clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024
NXL Ratings Summary
NXL Quant Ranking